功能神经障碍中的安慰剂:承诺和争议
Natalia Szejko1,2,3,4, Ali Abusrair5, Tomasz Pasierski2
1Clinic of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, 30-625 Hannover, Germany.
Healthcare (Basel, Switzerland)
|November 27, 2025
概括
安慰剂,nocebo和lessebo效应在神经和精神疾病中很常见. 它们在功能神经障碍 (FND) 中的使用由于伦理方面的担忧而受到争议,尽管有潜在的治疗益处.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 医学伦理 医学伦理
背景情况:
- 在神经和精神疾病中,安慰剂,nocebo和lessebo效应普遍存在.
- 安慰剂效应的神经机制与活性药物干预措施所针对的神经机制重叠.
- 功能神经障碍 (FNDs) 涉及安慰剂网络和功能障碍途径之间共享的神经基质.
研究的目的:
- 讨论在FND中使用安慰剂,nocebo和lessebo的应用.
- 探索在FND管理中使用这些效应的伦理含义.
- 检查围绕在FND诊断和治疗中使用安慰剂的争议.
主要方法:
- 文献综述和伦理分析.
- 讨论神经机制和共同的基板.
- 检查道德原则:知情同意,自主,非恶性,慈善和正义.
主要成果:
- 安慰剂效应与FND病理生理学共享神经基质,特别是在情绪调节,应激反应和自我代理方面.
- 在FND中使用安慰剂带来了重大的伦理挑战.
- 在FND的安慰剂干预被认为是有争议的,无论是用于诊断和治疗目的.
结论:
- 虽然可能是安全和独特的,但在FND中使用安慰剂引起了关于核心医学原则的伦理问题.
- 在FND中使用安慰剂挑战了医生与患者之间的关系,特别是关于自主性和开放性.
- 需要进一步的伦理审议来负责任地考虑在FND中使用安慰剂干预.
相关概念视频
The Placebo Effect
6.8K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.8K
Blind Procedures
12.8K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
12.8K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
523
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
523
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Psychosis: Goals of Pharmacotherapy
449
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
449


